Roche acquires Irish biotech firm Inflazome
Swiss pharma company to acquire biotech for $449m (€380m)
22nd September 2020
Latest news
GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval
Both PARP inhibitors receive positive opinions from CHMP
22nd September 2020
UK’s chief medical officers upgrade coronavirus alert level
Decision made following review of rising COVID-19 cases
22nd September 2020
Keytruda/Lenvima combo shows promise in hard-to-treat cancers
Data shows a range of responses in different tumours
21st September 2020
University of Edinburgh spinout Cellinta will develop gene therapies for cancer
Investors include SV Health Investors and Cancer Research UK
21st September 2020
Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer
Detailed results presented at ESMO also show benefit in prostate cancer
21st September 2020
CHMP backs seven new meds in September meeting
Positive opinions include Pacira's Exparel and two new vaccines from Sanofi
21st September 2020
BMS' Opdivo wins new NICE lung cancer backing
The drug has been approved for routine NHS commissioning for squamous or non-squamous NSCLC
18th September 2020
Bayer’s Vitrakvi shows long-term efficacy in TRK fusion-positive cancers
Tumour agnostic therapy demonstrates sustained efficacy
18th September 2020
Access to coronavirus tests should be ‘top priority’, says NHS Confederation director
Concerns over NHS Test and Trace system exacerbated by continuing rise in cases
18th September 2020
NICE u-turn sees Akcea's Waylivra win NHS funding
The drug is the first and only therapy for the ultra rare condition Familial Chylomicronaemia Syndrome (FCS)
18th September 2020
Shine bright in 2020!
The deadline for entering the 2020 PharmaTimes Communications Awards, Sales Awards and Marketer of the Year competitions has been extended to Friday October 2 after a last-minute spike in enquiries
17th September 2020
IVD industry must be supported in COVID-19 recovery strategy, says BIVDA
Industry body says in vitro diagnostics are vital to clearing the backlog of undiagnosed conditions
17th September 2020
Novartis’ Tafinlar plus Mekinist shows long-term benefit in advanced melanoma
Over half of patients treated with combination therapy were alive and relapse-free after five years
17th September 2020
AZ picks up oral PCSK9 inhibitor programme from Dogma
AZ will take the programme forward into clinical development
17th September 2020
